Skip to main content

Advertisement

Log in

Bombesin and bombesin antagonists: Studies in Swiss 3T3 cells and human small cell lung cancer

  • Experimental Oncology
  • Published:
British Journal of Cancer Submit manuscript

Abstract

Bombesins are potent growth factors for murine Swiss 3T3 cells. Using these cells in chemically defined conditions we have been able to characterise the bombesin receptor and the early signals preceding DNA synthesis. We describe two substance P analogues [DArg1, DPro2, DTrp7,9, Leu11] substance P and [DArg1, DPhe5, DTrp7,9, Leu11] substance P which competitively block the binding of bombesins to their receptor and all the events leading to mitogenesis. Bombesins are secreted by human small cell lung cancers (SCLC) and may act as autocrine growth factors for these tumours, so the development of peptide bombesin antagonists could have therapeutic implications. We demonstrate that the antagonists can reversibly inhibit the growth of SCLC in vitro, with relatively little effect on other lung tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Presented, by invitation at the BACR/CRC/ICRF Symposium on 'Growth factors', London, December 1987.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Woll, P., Rozengurt, E. Bombesin and bombesin antagonists: Studies in Swiss 3T3 cells and human small cell lung cancer. Br J Cancer 57, 579–586 (1988). https://doi.org/10.1038/bjc.1988.132

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.132

  • Springer Nature Limited

This article is cited by

Navigation